DD297064A5 - Reagens zum nachweis der fibrinolytischen aktivitaet - Google Patents

Reagens zum nachweis der fibrinolytischen aktivitaet Download PDF

Info

Publication number: DD297064A5
Authority: DD; German Democratic Republic
Prior art keywords: antibody; fibrinolytic enzyme; fibrinolytic; substance; labeled
Prior art date: 1989-08-18

Application number

DD90343498A

Other languages

German (de)

English (en)

Inventor

Johan Selmer

Niels Tromholt

Original Assignee

��@��@�a�k��

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-18

Filing date

1990-08-16

Publication date

1992-01-02

1990-08-16 Application filed by ��@��@�a�k�� filed Critical ��@��@�a�k��

1992-01-02 Publication of DD297064A5 publication Critical patent/DD297064A5/de

Links

239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 38
230000003480 fibrinolytic effect Effects 0.000 title claims abstract description 29
101710196208 Fibrinolytic enzyme Proteins 0.000 claims abstract description 54
239000000126 substance Substances 0.000 claims abstract description 32
241000282414 Homo sapiens Species 0.000 claims abstract description 24
238000001514 detection method Methods 0.000 claims abstract description 23
239000012634 fragment Substances 0.000 claims abstract description 22
238000001727 in vivo Methods 0.000 claims abstract description 19
230000027455 binding Effects 0.000 claims abstract description 17
241001465754 Metazoa Species 0.000 claims abstract description 13
108050006955 Tissue-type plasminogen activator Proteins 0.000 claims description 92
102100033571 Tissue-type plasminogen activator Human genes 0.000 claims description 92
229950003499 fibrin Drugs 0.000 claims description 24
102000009123 Fibrin Human genes 0.000 claims description 23
108010073385 Fibrin Proteins 0.000 claims description 23
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 23
230000002285 radioactive effect Effects 0.000 claims description 12
239000003527 fibrinolytic agent Substances 0.000 claims description 10
102000013566 Plasminogen Human genes 0.000 claims description 8
108010051456 Plasminogen Proteins 0.000 claims description 8
102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 7
108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 7
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 7
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 7
238000004519 manufacturing process Methods 0.000 claims description 7
238000002372 labelling Methods 0.000 claims description 6
229940012957 plasmin Drugs 0.000 claims description 6
229960005356 urokinase Drugs 0.000 claims description 6
229960000187 tissue plasminogen activator Drugs 0.000 claims description 5
108010088842 Fibrinolysin Proteins 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
241000792859 Enema Species 0.000 claims description 3
239000000443 aerosol Substances 0.000 claims description 3
239000007920 enema Substances 0.000 claims description 3
229940095399 enema Drugs 0.000 claims description 3
238000009472 formulation Methods 0.000 claims 1
239000007972 injectable composition Substances 0.000 claims 1
230000015556 catabolic process Effects 0.000 abstract description 4
238000006731 degradation reaction Methods 0.000 abstract description 4
208000007536 Thrombosis Diseases 0.000 description 36
238000002347 injection Methods 0.000 description 33
239000007924 injection Substances 0.000 description 33
230000000694 effects Effects 0.000 description 27
102000004190 Enzymes Human genes 0.000 description 20
108090000790 Enzymes Proteins 0.000 description 20
229940088598 enzyme Drugs 0.000 description 20
238000000034 method Methods 0.000 description 18
210000004369 blood Anatomy 0.000 description 16
239000008280 blood Substances 0.000 description 16
238000003745 diagnosis Methods 0.000 description 12
238000003384 imaging method Methods 0.000 description 12
241000283973 Oryctolagus cuniculus Species 0.000 description 9
210000002414 leg Anatomy 0.000 description 9
210000004185 liver Anatomy 0.000 description 9
238000009825 accumulation Methods 0.000 description 8
230000000702 anti-platelet effect Effects 0.000 description 7
239000003146 anticoagulant agent Substances 0.000 description 7
210000004027 cell Anatomy 0.000 description 7
230000001732 thrombotic effect Effects 0.000 description 7
241000282472 Canis lupus familiaris Species 0.000 description 6
108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
230000009467 reduction Effects 0.000 description 6
210000003462 vein Anatomy 0.000 description 6
230000008030 elimination Effects 0.000 description 5
238000003379 elimination reaction Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
238000001356 surgical procedure Methods 0.000 description 5
208000032843 Hemorrhage Diseases 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
206010047249 Venous thrombosis Diseases 0.000 description 4
210000001015 abdomen Anatomy 0.000 description 4
230000003187 abdominal effect Effects 0.000 description 4
230000008021 deposition Effects 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
230000004807 localization Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
230000002792 vascular Effects 0.000 description 4
208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 3
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
241001529936 Murinae Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010033128 Ovarian cancer Diseases 0.000 description 3
108010023197 Streptokinase Proteins 0.000 description 3
239000000427 antigen Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
230000008901 benefit Effects 0.000 description 3
208000034158 bleeding Diseases 0.000 description 3
230000000740 bleeding effect Effects 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000010367 cloning Methods 0.000 description 3
239000000306 component Substances 0.000 description 3
210000003191 femoral vein Anatomy 0.000 description 3
230000020764 fibrinolysis Effects 0.000 description 3
230000002440 hepatic effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
210000000952 spleen Anatomy 0.000 description 3
229960005202 streptokinase Drugs 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
238000011640 AKR mouse Methods 0.000 description 2
208000002109 Argyria Diseases 0.000 description 2
206010051055 Deep vein thrombosis Diseases 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
208000005189 Embolism Diseases 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
-1 For example Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
206010061535 Ovarian neoplasm Diseases 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
210000004102 animal cell Anatomy 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000012503 blood component Substances 0.000 description 2
210000004204 blood vessel Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
238000009826 distribution Methods 0.000 description 2
230000029142 excretion Effects 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
210000002683 foot Anatomy 0.000 description 2
210000000245 forearm Anatomy 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
208000030304 gastrointestinal bleeding Diseases 0.000 description 2
210000002149 gonad Anatomy 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
210000004408 hybridoma Anatomy 0.000 description 2
230000000984 immunochemical effect Effects 0.000 description 2
229910052738 indium Inorganic materials 0.000 description 2
APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 2
210000003127 knee Anatomy 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
229960003330 pentetic acid Drugs 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
239000002243 precursor Substances 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
230000004044 response Effects 0.000 description 2
239000000243 solution Substances 0.000 description 2
210000004989 spleen cell Anatomy 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
238000012800 visualization Methods 0.000 description 2
206010003178 Arterial thrombosis Diseases 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
241000282465 Canis Species 0.000 description 1
206010008030 Cerebellar haemorrhage Diseases 0.000 description 1
206010008111 Cerebral haemorrhage Diseases 0.000 description 1
206010008132 Cerebral thrombosis Diseases 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
206010011091 Coronary artery thrombosis Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
229910052688 Gadolinium Inorganic materials 0.000 description 1
208000000616 Hemoptysis Diseases 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010048620 Intracardiac thrombus Diseases 0.000 description 1
201000001429 Intracranial Thrombosis Diseases 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010051077 Post procedural haemorrhage Diseases 0.000 description 1
208000010378 Pulmonary Embolism Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
206010039203 Road traffic accident Diseases 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
108010003723 Single-Domain Antibodies Proteins 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000024248 Vascular System injury Diseases 0.000 description 1
208000012339 Vascular injury Diseases 0.000 description 1
206010047115 Vasculitis Diseases 0.000 description 1
206010065441 Venous haemorrhage Diseases 0.000 description 1
208000002223 abdominal aortic aneurysm Diseases 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
210000003423 ankle Anatomy 0.000 description 1
210000000702 aorta abdominal Anatomy 0.000 description 1
208000007474 aortic aneurysm Diseases 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
244000309466 calf Species 0.000 description 1
208000002458 carcinoid tumor Diseases 0.000 description 1
210000004534 cecum Anatomy 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
208000002528 coronary thrombosis Diseases 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
238000010828 elution Methods 0.000 description 1
230000003073 embolic effect Effects 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
210000001105 femoral artery Anatomy 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
230000004927 fusion Effects 0.000 description 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 description 1
201000005917 gastric ulcer Diseases 0.000 description 1
208000006750 hematuria Diseases 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
208000034783 hypoesthesia Diseases 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000003902 lesion Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
230000005291 magnetic effect Effects 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
210000002850 nasal mucosa Anatomy 0.000 description 1
238000010606 normalization Methods 0.000 description 1
238000009206 nuclear medicine Methods 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
230000005298 paramagnetic effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
210000003513 popliteal vein Anatomy 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000013014 purified material Substances 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
239000012217 radiopharmaceutical Substances 0.000 description 1
229940121896 radiopharmaceutical Drugs 0.000 description 1
230000002799 radiopharmaceutical effect Effects 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000013589 supplement Substances 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
210000003384 transverse colon Anatomy 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
230000003519 ventilatory effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/972—Plasminogen activators
- G01N2333/9726—Tissue plasminogen activator

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
General Health & Medical Sciences (AREA)
Food Science & Technology (AREA)
Analytical Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Investigating Or Analysing Biological Materials (AREA)

DD90343498A 1989-08-18 1990-08-16 Reagens zum nachweis der fibrinolytischen aktivitaet DD297064A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DK408289A DK408289D0 (da)	1989-08-18	1989-08-18	Diagnostisk reagens

Publications (1)

Publication Number	Publication Date
DD297064A5 true DD297064A5 (de)	1992-01-02

Family

ID=8129992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DD90343498A DD297064A5 (de)	1989-08-18	1990-08-16	Reagens zum nachweis der fibrinolytischen aktivitaet

Country Status (18)

Country	Link
US (1)	US5165912A (fr)
EP (1)	EP0487594B1 (fr)
JP (1)	JPH04507254A (fr)
KR (1)	KR920703120A (fr)
AT (1)	ATE92770T1 (fr)
AU (1)	AU639940B2 (fr)
CA (1)	CA2065147A1 (fr)
CZ (1)	CZ280904B6 (fr)
DD (1)	DD297064A5 (fr)
DE (1)	DE69002769T2 (fr)
DK (2)	DK408289D0 (fr)
ES (1)	ES2058931T3 (fr)
FI (1)	FI920669A0 (fr)
IE (1)	IE65525B1 (fr)
IL (1)	IL95407A (fr)
NO (1)	NO920624D0 (fr)
NZ (1)	NZ234937A (fr)
WO (1)	WO1991002546A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6964764B2 (en) *	1999-11-13	2005-11-15	Talecris Biotherapeutics, Inc.	Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
US6355243B1 (en)	1999-11-13	2002-03-12	Bayer Corporation	Method of thrombolysis by local delivery of active plasmin
US7544500B2 (en) *	1999-11-13	2009-06-09	Talecris Biotherapeutics, Inc.	Process for the production of a reversibly inactive acidified plasmin composition
US20080167544A1 (en) *	2006-12-01	2008-07-10	Cold Spring Diagnostics, Inc.	Compositions And Methods For Locating An Internal Bleeding Site
UA103771C2 (ru) *	2008-06-04	2013-11-25	Грифолз Терапьютикс Инк.	Стрептокиназа, активирующая плазмин, способ и набор для получения плазмина
JP5789521B2 (ja)	2009-03-03	2015-10-07	グリフオルス・セラピユーテイクス・インコーポレーテツドＧｒｉｆｏｌｓＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	プラスミノーゲンを製造するための組成物、方法およびキット；ならびにそれから製造されるプラスミン

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0169232B1 (fr) *	1984-01-23	1990-04-25	For Energiteknikk Institutt	Composition pour le marquage au technetium -99m de matières protéiques
US4659839A (en) *	1984-10-10	1987-04-21	Mallinckrodt, Inc.	Coupling agents for radiolabeled antibody fragments
CA1285223C (fr) *	1986-11-10	1991-06-25	New England Deaconess Hospital	Detection des affections vasculaires

1989
- 1989-08-18 DK DK408289A patent/DK408289D0/da not_active Application Discontinuation
1990
- 1990-08-16 FI FI920669A patent/FI920669A0/fi not_active Application Discontinuation
- 1990-08-16 WO PCT/DK1990/000210 patent/WO1991002546A1/fr not_active Ceased
- 1990-08-16 CA CA002065147A patent/CA2065147A1/fr not_active Abandoned
- 1990-08-16 AU AU62859/90A patent/AU639940B2/en not_active Ceased
- 1990-08-16 EP EP90912800A patent/EP0487594B1/fr not_active Expired - Lifetime
- 1990-08-16 DK DK90912800.1T patent/DK0487594T3/da active
- 1990-08-16 JP JP2512113A patent/JPH04507254A/ja active Pending
- 1990-08-16 DE DE90912800T patent/DE69002769T2/de not_active Expired - Fee Related
- 1990-08-16 KR KR1019920700340A patent/KR920703120A/ko not_active Ceased
- 1990-08-16 DD DD90343498A patent/DD297064A5/de not_active IP Right Cessation
- 1990-08-16 AT AT90912800T patent/ATE92770T1/de not_active IP Right Cessation
- 1990-08-16 NZ NZ234937A patent/NZ234937A/xx unknown
- 1990-08-16 ES ES90912800T patent/ES2058931T3/es not_active Expired - Lifetime
- 1990-08-17 IL IL9540790A patent/IL95407A/en not_active IP Right Cessation
- 1990-08-17 IE IE297790A patent/IE65525B1/en not_active IP Right Cessation
- 1990-08-17 US US07/569,127 patent/US5165912A/en not_active Expired - Fee Related
- 1990-08-17 CZ CS904047A patent/CZ280904B6/cs unknown
1992
- 1992-02-17 NO NO920624A patent/NO920624D0/no unknown

Also Published As

Publication number	Publication date
CZ280904B6 (cs)	1996-05-15
IL95407A0 (en)	1991-06-30
DE69002769T2 (de)	1993-12-02
US5165912A (en)	1992-11-24
JPH04507254A (ja)	1992-12-17
NZ234937A (en)	1991-11-26
ATE92770T1 (de)	1993-08-15
KR920703120A (ko)	1992-12-17
ES2058931T3 (es)	1994-11-01
NO920624L (no)	1992-02-17
AU6285990A (en)	1991-04-03
CZ404790A3 (en)	1996-01-17
DE69002769D1 (de)	1993-09-16
DK408289D0 (da)	1989-08-18
WO1991002546A1 (fr)	1991-03-07
FI920669A7 (fi)	1992-02-17
CA2065147A1 (fr)	1991-02-19
IL95407A (en)	1994-07-31
FI920669A0 (fi)	1992-02-17
IE65525B1 (en)	1995-11-01
DK0487594T3 (da)	1994-01-03
IE902977A1 (en)	1991-02-27
AU639940B2 (en)	1993-08-12
NO920624D0 (no)	1992-02-17
EP0487594A1 (fr)	1992-06-03
EP0487594B1 (fr)	1993-08-11

Legal Events

Date	Code	Title	Description
2000-01-20	ENJ	Ceased due to non-payment of renewal fee

Publication	Publication Date	Title
DE3486030T2 (de)	1993-05-19	Monoklonale antikoerper, spezifisch von in vivo von fibrinogen abgeleiteten derivatstuecken.
DE69006728T2 (de)	1994-08-25	Abbildungsverfahren für arteriosklerotische plaque.
DE69215870T2 (de)	1997-05-22	Feststellung kardiovaskulärer läsionen
DE69121272T2 (de)	1997-01-09	Bispezifische monoklonale Antikörper, ihre Produktion und Verwendung
Border et al.	1982	Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen: Demonstration of a pathogenic role for electrical charge
DE3750630T2 (de)	1995-05-04	Verwendung von einem Antikörperkonjugat zum Nachweis von nekrotischem malignem Gewebe und für die assoziierte Therapie.
DE69229911T2 (de)	2000-01-20	Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen
DE3883522T2 (de)	1994-03-24	Verfahren zum diagnostizieren von blutpfropfen mit fibrin-bindenden proteinen.
DE69131539T2 (de)	2000-05-04	Polypeptide mit fibrinbindungsdomäne, verwendungen und verfahren zu deren herstellung
DE3850497T2 (de)	1995-02-23	Methode zur markierung von antikörpern mit einem metallion.
EP0480440A1 (fr)	1992-04-15	Anticorps monoclonal contre le mélanome
DE69002769T2 (de)	1993-12-02	Mittel zum nachweis einer fibrinolytischen wirkung.
Cerqueira et al.	1992	Noninvasive arterial thrombus imaging with 99mTc monoclonal antifibrin antibody.
DE3689779T2 (de)	1994-09-29	Plättcheninhibierender Teil eines monoklonalen Antikörpers.
DE69526542T2 (de)	2003-01-09	uPA-Bindungstelle auf 2+3 Domäne von uPAR und damit reagierende Antikörper
Bautovich et al.	1994	Detection of deep venous thrombi and pulmonary embolus with technetium-99m-DD-3B6/22 anti-fibrin monoclonal antibody Fab′ fragment
Siegel et al.	1972	Scanning of thromboemboli with 131I-streptokinase
DE69413009T2 (de)	1999-03-25	Verwendung von antikörpern gegen pdgf-rezeptoren zur inhibierung von hyperplasie der intima
DE3854926T2 (de)	1996-05-30	Verwendung von antikörper gegen angiogenin: immunotherapeutische mittel
DE3750434T3 (de)	1999-04-08	Verwendung eines detektierbaren, markierten, Immunoglobulins oder eines Fragmentes davon zur Herstellung eines Mittels für den Nachweis eines Entzündungsherdes in vivo.
EP0589982B1 (fr)	2001-01-17	Anticorps monoclonaux contre la proteine i de liaison du facteur de necrose tumorale humain (p i de liaison du tnf)
Ciavolella et al.	1999	Immunoscintigraphy of atherosclerotic uncomplicated lesions in vivo with a monoclonal antibody against D-dimers of insoluble fibrin
DE60127081T2 (de)	2008-01-10	Gegen den aktiven, jedoch nicht den inaktiven Hepatozytenwachstumsfaktoraktivator (HGFA) gerichteter spezifischer Antikörper
EP0540588B1 (fr)	1995-06-21	Composition assurant une meilleure elimination de substances bioactives contenues dans le systeme sanguin
Ciavolella et al.	1999	Immunoscintigraphy of venous thrombi: clinical effectiveness of a new antifibrin D-dimer monoclonal antibody